N	Concordance
1	osyl extensions) from bacillus Calmette Guerin leading to the obtention of two t
2	ponse to intravesical Bacillus Calmette Guerin (BCG) immunotherapy was assessed 
3	red with reference to Bacillus Calmette Guerin (BCG) vaccine in the mice challen
4	 tumor stage or prior bacillus Calmette Guerin treatment. Median followup was 22
5	PURPOSE: Intravesical bacillus Calmette-Guerin (BCG) was used to palliate severe
6	sical instillation of bacillus Calmette-Guerin (BCG) vaccine has been shown to b
7	treatment. Presently, bacillus Calmette-Guerin (BCG) immunotherapy remains the m
8	es, contribute to the bacillus Calmette-Guerin (BCG)-induced local immunological
9	usly that heat-killed bacillus Calmette-Guerin injected into the brain parenchym
10	lial cell vaccine and Bacillus Calmette-Guerin (BCG) adjuvant are injected once
11	ate matrix applied to Bacillus Calmette-Guerin (BCG) has been developed. Small-d